Hopital Europeen Marseille

The department of internal medicine at Hopital Europeen Marseille is conducting a series of studies aimed at improving outcomes for patients with non‑small cell lung cancer. Trials evaluate adjuvant immunotherapy, targeted agents, and maintenance strategies to increase disease‑free and overall survival.

• Advanced stage NSCLC eligible for PD‑1 antagonist therapy
• Completely resected stage I‑IIIA non‑squamous NSCLC
• PD‑L1 positive tumors (TC ≥ 25%)
• EGFR‑/ALK‑negative disease
• Maintenance pembrolizumab ± pemetrexed after induction

These investigations reflect a commitment to personalized oncology and the integration of immunotherapy into standard lung‑cancer care.

A portfolio of studies focuses on breast cancer subtypes, testing novel anti‑HER2 agents, PARP inhibitors, and endocrine‑based regimens. The goal is to enhance response rates and reduce recurrence in both early‑stage and metastatic settings.

• HER2‑positive locally advanced or metastatic breast cancer
• Premenopausal HR‑positive/HER2‑negative high‑risk disease
• Germline BRCA‑mutated high‑risk HER2‑negative primary breast cancer
• ER+/HER2‑negative metastatic disease
• Adjuvant therapy guided by molecular risk assessment

The trials aim to personalize treatment pathways and improve long‑term survival for women with breast cancer.

Research at the site addresses a range of gastro‑intestinal cancers, including colorectal, pancreatic, biliary, and gastric tumors. Studies compare intensive chemotherapy regimens, targeted therapies, and immunotherapy combinations to optimize curative and palliative outcomes.

• Metastatic RAS/BRAF wild‑type colorectal cancer
• Microsatellite unstable or mismatch‑repair deficient rectal cancer
• Advanced biliary cancer
• Pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX
• Ampullary adenocarcinoma adjuvant chemotherapy
• Gastric or gastro‑oesophageal junction adenocarcinoma progressing after peri‑operative therapy

These trials seek to refine therapeutic sequencing and identify biomarkers that predict benefit from emerging agents.

The internal medicine team is evaluating innovative approaches for autoimmune diseases, including novel biologics and targeted small molecules. Objectives center on reducing relapse rates, limiting organ damage, and improving quality of life.

• Relapsing‑remitting multiple sclerosis
• Cutaneous lupus erythematosus
• Granulomatosis with polyangiitis with inadequate response to standard care
• Takayasu arteritis refractory to conventional therapy
• Lupus nephritis induction without oral corticosteroids

By testing agents such as remibrutinib, tocilizumab, and selective JAK inhibitors, the trials aim to expand therapeutic options for patients with challenging immune‑mediated conditions.

A series of investigations target chronic respiratory conditions, focusing on disease control, exacerbation reduction, and symptom relief. The studies evaluate inhaled combinations, biologics, and novel cough suppressants.

• Chronic obstructive pulmonary disease (COPD)
• Severe eosinophilic asthma previously treated with anti‑IL‑5/5R therapy
• Refractory or unexplained chronic cough
• Bronchodilator triple therapy versus dual therapy on cardiopulmonary outcomes

These trials aim to improve lung function, reduce emergency visits, and enhance daily living for patients with chronic respiratory disease.

Ongoing work addresses chronic viral infections, with a focus on innovative antiviral agents and therapeutic vaccines. Objectives include achieving sustained viral suppression and reducing liver disease progression.

• HIV‑1 infection under antiretroviral therapy
• Chronic hepatitis B virus infection
• HIV/HBV coinfection with dual antiviral management
• Long‑acting HIV pre‑exposure prophylaxis (PrEP) agents

The studies seek to deepen understanding of viral dynamics and provide new treatment options for individuals living with these infections.